Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial
about
Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancerHuman epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic optionsHealth economic aspects of breast cancer treatment: the compulsory health insurances' viewBeyond RAS and BRAF: a target rich disease that is ripe for pickingUnravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsTwenty years of anti-HER2 therapy-associated cardiotoxicityEfficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-AnalysisCancer drug related cardiotoxicity during breast cancer treatment.Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials.Dual HER2 blockade: preclinical and clinical dataPertuzumab and breast cancer: another piece in the anti-HER2 puzzle.Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell TransplantationCurrent Approaches and Emerging Directions in HER2-resistant Breast Cancer.Modeling the relationship between progression-free survival and overall survival: the phase II/III trial.Therapeutic Considerations in Treating HER2-Positive Metastatic Breast CancerMeeting highlights: the first korean breast cancer treatment consensus conference.The role of HER-2 in Breast CancerEfficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study.Phase II study of Pseudomonas aeruginosa-Mannose-Sensitive hemagglutinin in combination with capecitabine for Her-2-negative metastatic breast cancer pretreated with anthracycline and taxane.Targeted therapy in her2-positive metastatic breast cancer: a review of the literature.HER2-directed therapy: current treatment options for HER2-positive breast cancer.Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer.Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study.Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?Lapatinib for advanced or metastatic breast cancerLabel-free LC-MS analysis of HER2+ breast cancer cell line response to HER2 inhibitor treatment.The Impacts of Inclusion in Clinical Trials on Outcomes among Patients with Metastatic Breast Cancer (MBC).Combination drug delivery approaches in metastatic breast cancerPredictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study.HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.Clinical significance of glycoprotein nonmetastatic B and its association with HER2 in breast cancer.A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer.Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidenceThe benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer--a systematic reviewIs the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy.Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer CellsAnti-HER2 Therapy Beyond Second-Line for HER2-Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel.A gene expression profile indicative of early stage HER2 targeted therapy responseUnited States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignanciesPertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer
P2860
Q24202199-3F93EF10-2B51-49D2-BDFE-1966EFE59FB4Q26777681-615246B2-06BC-4AF3-BE9D-403D7D944F07Q26826505-7EC05690-81B6-4961-B1D4-DD775A746F14Q28066095-5F7B786D-F618-4B3D-98F1-D40FA3245133Q28075291-66DB6F6C-ABC8-49ED-9B2B-3B3663CD270FQ28079391-983FED4A-0EB0-45DE-B4B6-716A71889DDFQ28547354-B663A5E6-5F27-4C34-8E43-DAD1A8940162Q30251498-070DC785-6485-42E1-9DDD-0B409067C645Q30857631-0A9262AD-DA77-44B5-8B59-C869511C31B5Q30941327-FB2ACBA7-B540-44D4-8A18-B377F88B87D8Q33364587-7E65BF84-0CB6-439A-B29D-D8E8D24546B9Q33411110-44D3F05F-165D-4CFC-A738-50C6258D4DA4Q34016480-4CE62C40-6CFB-4DF9-894D-0B5FD15FF488Q34040130-359F76EF-C24B-46B2-8A15-01BAA03A3C3AQ34268618-0F396E92-DA8B-4EA1-A64D-8FA1CDD514ADQ34779593-24AFA560-EF24-48BC-BF42-50F05517E1C9Q35068343-5BA003D7-1E49-43ED-AA29-B7E4B92A1D48Q35092651-611D0526-9E2F-4662-81F5-08CAC0FC2C68Q35175762-D5B872F4-4A40-4354-B29B-89B65CF90E2FQ35239603-F06A26BB-6611-4B49-B9F6-4AE3DB9ABD9AQ35551522-3FCD30A8-83A9-4BB7-B55C-55AB10B5B44DQ35653820-D904F0EC-2413-4C4F-8471-D1CFB425CA41Q35777143-B00493D7-22D7-4D0A-BF4C-4BAA36CD9CF7Q35815486-1FDE4C56-A1F0-41B5-8787-06116034D319Q35913209-458C1046-2FD8-40EE-A0AB-8859BD778092Q35914446-63B1C1E6-872C-4FB4-B641-1DD722F232A6Q35930745-4D558386-64D6-4003-A81A-7BC020900EE6Q35955198-37FAA471-0B8C-4D2C-8CC0-39B58D4BBFE0Q36029360-C179F708-FF88-436F-B06A-1ED18E4B4C95Q36040463-15B81B3C-10CD-49D9-B669-B115A42B7041Q36051772-8D7B92A0-A262-4DBD-9860-2B1C37F3957EQ36095920-41659F04-9BF0-4D0A-815C-5288635BDAB7Q36250585-B8F03C89-D342-4E0C-A7E5-B306B2A3BD46Q36294151-742BA753-74EC-47B9-82A0-ABA83C806349Q36440625-DB136128-9507-4EB8-8B92-4ADAC58282FAQ36482500-791A7139-F349-4E54-AAE3-64E3902D32B6Q36938365-3CD8DAD4-76B5-4CD1-A32C-2CC06FA81B67Q37049733-5A5F7383-783D-4BA5-96DF-CF4B7A4206C8Q37142970-E689B3BF-8A4A-4A13-BC6E-1E47A04224EFQ37205749-CEC294CB-8C2B-4F14-8E86-FA319B93867A
P2860
Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Lapatinib plus capecitabine in ...... f a phase III randomized trial
@ast
Lapatinib plus capecitabine in ...... f a phase III randomized trial
@en
type
label
Lapatinib plus capecitabine in ...... f a phase III randomized trial
@ast
Lapatinib plus capecitabine in ...... f a phase III randomized trial
@en
prefLabel
Lapatinib plus capecitabine in ...... f a phase III randomized trial
@ast
Lapatinib plus capecitabine in ...... f a phase III randomized trial
@en
P2093
P2860
P1433
P1476
Lapatinib plus capecitabine in ...... f a phase III randomized trial
@en
P2093
Bradley Imwalle
Charles E Geyer
David Cameron
Michelle Casey
P2860
P304
P356
10.1634/THEONCOLOGIST.2009-0181
P577
2010-08-24T00:00:00Z